China Universal Asset Management Co. Ltd. Has $171,000 Holdings in Zymeworks Inc. (NYSE:ZYME)

China Universal Asset Management Co. Ltd. grew its position in Zymeworks Inc. (NYSE:ZYME) by 64.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,665 shares of the company’s stock after purchasing an additional 5,359 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Zymeworks were worth $171,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Susquehanna Fundamental Investments LLC acquired a new position in Zymeworks in the 1st quarter worth about $579,000. O Shaughnessy Asset Management LLC increased its holdings in shares of Zymeworks by 51.5% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 255,497 shares of the company’s stock valued at $2,688,000 after acquiring an additional 86,797 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Zymeworks during the 2nd quarter valued at about $1,683,000. Rubric Capital Management LP increased its holdings in shares of Zymeworks by 12.7% during the 2nd quarter. Rubric Capital Management LP now owns 3,917,331 shares of the company’s stock valued at $33,336,000 after acquiring an additional 441,947 shares during the last quarter. Finally, Squarepoint Ops LLC increased its holdings in shares of Zymeworks by 401.9% during the 2nd quarter. Squarepoint Ops LLC now owns 73,324 shares of the company’s stock valued at $624,000 after acquiring an additional 58,716 shares during the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

Zymeworks Stock Up 1.2 %

Shares of NYSE:ZYME opened at $13.87 on Thursday. The business has a 50 day moving average price of $12.44 and a 200 day moving average price of $10.38. Zymeworks Inc. has a twelve month low of $6.79 and a twelve month high of $14.05. The company has a market cap of $980.68 million, a price-to-earnings ratio of -7.75 and a beta of 1.20.

Zymeworks (NYSE:ZYME) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.01. Zymeworks had a negative return on equity of 21.97% and a negative net margin of 179.42%. The company had revenue of $19.24 million during the quarter, compared to the consensus estimate of $23.16 million. During the same quarter last year, the company earned ($0.76) EPS. Analysts anticipate that Zymeworks Inc. will post -0.85 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Stifel Nicolaus increased their price objective on Zymeworks from $21.00 to $28.00 and gave the company a “buy” rating in a report on Monday. HC Wainwright restated a “neutral” rating and set a $12.00 target price on shares of Zymeworks in a research note on Tuesday, October 22nd.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.